Drug intelligence / Profile preview

HMO2

Development stage: Preclinical
Lead developer: Glycom
Administration: Oral

Overview

HMO2 is a specific human milk oligosaccharide (HMO) being investigated as a dietary supplement. It is currently in clinical trials to assess its effects on faecal microbiota, gastrointestinal symptoms, mucosal immunity, and gut barrier function in adult patients with Irritable Bowel Syndrome (IBS). The study aims to establish its impact on gut health and overall quality of life in IBS patients.

Other names: HMO 2HMO2HMO-2

Beyond the preview

Go deeper on HMO2.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HMO2.

Explore the full profile